ZA200404812B - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. - Google Patents
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. Download PDFInfo
- Publication number
- ZA200404812B ZA200404812B ZA200404812A ZA200404812A ZA200404812B ZA 200404812 B ZA200404812 B ZA 200404812B ZA 200404812 A ZA200404812 A ZA 200404812A ZA 200404812 A ZA200404812 A ZA 200404812A ZA 200404812 B ZA200404812 B ZA 200404812B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- heterocyclo
- cycloalkenyl
- cycloalkyl
- aryl
- Prior art date
Links
- 102000007399 Nuclear hormone receptor Human genes 0.000 title claims description 80
- 108020005497 Nuclear hormone receptor Proteins 0.000 title claims description 80
- -1 heterocyclic succinimide compounds Chemical class 0.000 title claims description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 224
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 188
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 183
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 134
- 125000003118 aryl group Chemical group 0.000 claims description 116
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 112
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 111
- 125000003107 substituted aryl group Chemical group 0.000 claims description 107
- 125000003342 alkenyl group Chemical group 0.000 claims description 103
- 125000000304 alkynyl group Chemical group 0.000 claims description 96
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 95
- 125000000217 alkyl group Chemical group 0.000 claims description 94
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 94
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 92
- 229910052717 sulfur Inorganic materials 0.000 claims description 57
- 125000004414 alkyl thio group Chemical group 0.000 claims description 46
- 229910052760 oxygen Inorganic materials 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 150000003431 steroids Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 15
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 11
- 108010038795 estrogen receptors Proteins 0.000 claims description 10
- 102100032187 Androgen receptor Human genes 0.000 claims description 9
- 108010080146 androgen receptors Proteins 0.000 claims description 9
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 125000003367 polycyclic group Chemical group 0.000 claims description 9
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- BUIMWOLDCCGZKZ-UHFFFAOYSA-N n-hydroxynitramide Chemical compound ON[N+]([O-])=O BUIMWOLDCCGZKZ-UHFFFAOYSA-N 0.000 claims description 8
- 108090000468 progesterone receptors Proteins 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 7
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 6
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 229960003604 testosterone Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 22
- 239000000126 substance Substances 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 229940002612 prodrug Drugs 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 150000003573 thiols Chemical class 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 150000004702 methyl esters Chemical class 0.000 claims 5
- 102100038595 Estrogen receptor Human genes 0.000 claims 4
- 102100025803 Progesterone receptor Human genes 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 108010020650 COUP Transcription Factor II Proteins 0.000 claims 3
- 102100028226 COUP transcription factor 2 Human genes 0.000 claims 3
- 102100021316 Mineralocorticoid receptor Human genes 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108091008730 RAR-related orphan receptors β Proteins 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 150000002009 diols Chemical class 0.000 claims 2
- 230000033444 hydroxylation Effects 0.000 claims 2
- 238000005805 hydroxylation reaction Methods 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical compound C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 claims 2
- 125000004889 1-methylethylamino group Chemical group CC(C)N* 0.000 claims 1
- UKFPAGCSDWQXFT-UHFFFAOYSA-N 3-phenyl-4,5-dihydro-1,2-oxazole Chemical compound O1CCC(C=2C=CC=CC=2)=N1 UKFPAGCSDWQXFT-UHFFFAOYSA-N 0.000 claims 1
- WLDMPODMCFGWAA-UHFFFAOYSA-N 3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione Chemical compound C1CCCC2C(=O)NC(=O)C21 WLDMPODMCFGWAA-UHFFFAOYSA-N 0.000 claims 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 230000031154 cholesterol homeostasis Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000008102 immune modulation Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 238000007142 ring opening reaction Methods 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 230000009469 supplementation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 description 17
- 108020001756 ligand binding domains Proteins 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 102000015694 estrogen receptors Human genes 0.000 description 6
- 125000001475 halogen functional group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 2
- 102000016978 Orphan receptors Human genes 0.000 description 2
- 108070000031 Orphan receptors Proteins 0.000 description 2
- 108010001511 Pregnane X Receptor Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 102000004164 orphan nuclear receptors Human genes 0.000 description 2
- 108090000629 orphan nuclear receptors Proteins 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001783 near-resonance Rayleigh scattering spectroscopy Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 102200160920 rs35304565 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2511601A | 2001-12-19 | 2001-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200404812B true ZA200404812B (en) | 2005-08-26 |
Family
ID=27609007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200404812A ZA200404812B (en) | 2001-12-19 | 2004-06-17 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1458723B1 (pl) |
| JP (1) | JP2005523257A (pl) |
| KR (1) | KR20040086248A (pl) |
| CN (1) | CN1589271A (pl) |
| AR (1) | AR037950A1 (pl) |
| AT (1) | ATE411319T1 (pl) |
| AU (1) | AU2002361785B2 (pl) |
| BR (1) | BR0215281A (pl) |
| CA (1) | CA2471342A1 (pl) |
| CO (1) | CO5640082A2 (pl) |
| DE (1) | DE60229435D1 (pl) |
| DK (1) | DK1458723T3 (pl) |
| ES (1) | ES2314127T3 (pl) |
| GE (1) | GEP20063817B (pl) |
| HR (1) | HRP20040567A2 (pl) |
| HU (1) | HUP0402554A3 (pl) |
| IL (1) | IL162547A0 (pl) |
| IS (1) | IS7324A (pl) |
| MX (1) | MXPA04005876A (pl) |
| NO (1) | NO20043068L (pl) |
| NZ (1) | NZ533471A (pl) |
| PL (1) | PL370904A1 (pl) |
| PT (1) | PT1458723E (pl) |
| RU (1) | RU2330038C2 (pl) |
| SI (1) | SI1458723T1 (pl) |
| TW (1) | TWI263640B (pl) |
| UA (1) | UA78265C2 (pl) |
| UY (1) | UY27595A1 (pl) |
| WO (1) | WO2003062241A1 (pl) |
| YU (1) | YU53604A (pl) |
| ZA (1) | ZA200404812B (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7202264B2 (en) | 2003-01-31 | 2007-04-10 | Isis Pharmaceuticals, Inc. | Supports for oligomer synthesis |
| FR2860793A1 (fr) * | 2003-10-14 | 2005-04-15 | Entomed | Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations |
| WO2005049621A1 (en) * | 2003-11-13 | 2005-06-02 | Isis Pharmaceuticals, Inc. | 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis |
| US7605264B2 (en) | 2004-01-16 | 2009-10-20 | Bristol-Myers Squibb Company | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7569689B2 (en) | 2004-01-16 | 2009-08-04 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7253283B2 (en) | 2004-01-16 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7326728B2 (en) | 2004-01-16 | 2008-02-05 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof |
| US7625921B2 (en) | 2004-01-16 | 2009-12-01 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| JP4880583B2 (ja) * | 2004-03-17 | 2012-02-22 | ファイザー・プロダクツ・インク | 新規なベンジル（ベンジリデン）−ラクタム誘導体 |
| US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7361654B2 (en) | 2005-01-13 | 2008-04-22 | Bristol-Myers Squibb Co. | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7642273B2 (en) | 2005-01-13 | 2010-01-05 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007032936A2 (en) * | 2005-09-09 | 2007-03-22 | Schering Corporation | Azafused cyclin dependent kinase inhibitors |
| WO2008042571A2 (en) | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
| WO2008157291A2 (en) * | 2007-06-15 | 2008-12-24 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION |
| CN102459221A (zh) * | 2009-04-30 | 2012-05-16 | 住友化学株式会社 | 噻吩衍生物 |
| WO2011007819A1 (ja) | 2009-07-17 | 2011-01-20 | 塩野義製薬株式会社 | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 |
| CA2773615A1 (en) | 2009-09-11 | 2011-03-17 | Arwed Cleve | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| DK2523731T3 (en) | 2010-01-14 | 2019-02-04 | Novartis Ag | Use of an adrenal hormone modifier |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| WO2014179564A1 (en) * | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
| JP6156074B2 (ja) * | 2013-11-08 | 2017-07-05 | 住友化学株式会社 | スクシンイミド化合物及びその用途 |
| KR102408261B1 (ko) | 2014-02-03 | 2022-06-10 | 비타이 파마슈티컬즈, 엘엘씨 | Ror-감마의 디하이드로피롤로피리딘 저해제 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| PL3372584T3 (pl) * | 2014-12-19 | 2021-07-05 | Aragon Pharmaceuticals, Inc. | Sposób wytwarzania związku diarylotiohydantoiny |
| US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| KR20200052995A (ko) * | 2015-01-20 | 2020-05-15 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11279683B2 (en) | 2016-12-29 | 2022-03-22 | Enyo Pharma | Thiophene derivatives as antiviral agents |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115650976A (zh) | 2017-07-24 | 2023-01-31 | 生命医药有限责任公司 | RORγ的抑制剂 |
| EP4121044A4 (en) * | 2020-03-20 | 2024-03-13 | University Of Southern California | REGULATION OF THE ANDROGEN RECEPTOR BY SMALL MOLECULE ENANTIOMERS |
| TW202208356A (zh) | 2020-05-08 | 2022-03-01 | 美商哈利亞製藥公司 | Ｎｅｋ７激酶抑制劑 |
| CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
| WO2023154939A2 (en) * | 2022-02-14 | 2023-08-17 | The Johns Hopkins University | Gcpii inhibition for the treatment of sarcopenia and aging |
| WO2024059200A1 (en) | 2022-09-14 | 2024-03-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320270A (en) * | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
| US3215597A (en) * | 1963-10-30 | 1965-11-02 | Dow Chemical Co | Methods and compositions for use in animal husbandry |
| US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
| US4892943A (en) * | 1985-10-16 | 1990-01-09 | American Home Products Corporation | Fused bicyclic imides with psychotropic activity |
| JPS63170383A (ja) * | 1987-02-26 | 1988-07-14 | Nippon Zeon Co Ltd | 脂環式ジカルボン酸イミド化合物 |
| CA2069318A1 (en) * | 1989-10-27 | 1991-04-28 | Engelbert Ciganek | (n-phthalimidoalkyl) piperidines |
| CN1103769C (zh) * | 1996-10-25 | 2003-03-26 | 第一制药株式会社 | 三环胺衍生物 |
| FR2764890B1 (fr) * | 1997-06-24 | 1999-08-27 | Adir | Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2002533345A (ja) * | 1998-12-22 | 2002-10-08 | イーライ・リリー・アンド・カンパニー | 置換三環式化合物 |
| MXPA02012605A (es) * | 2000-06-28 | 2003-05-14 | Squibb Bristol Myers Co | Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso. |
| BR0113980A (pt) * | 2000-09-19 | 2003-06-24 | Bristol Myers Squibb Co | Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear |
-
2002
- 2002-12-13 TW TW091136163A patent/TWI263640B/zh active
- 2002-12-18 SI SI200230767T patent/SI1458723T1/sl unknown
- 2002-12-18 BR BR0215281-9A patent/BR0215281A/pt not_active IP Right Cessation
- 2002-12-18 KR KR10-2004-7009794A patent/KR20040086248A/ko not_active Application Discontinuation
- 2002-12-18 HU HU0402554A patent/HUP0402554A3/hu unknown
- 2002-12-18 CN CNA028281063A patent/CN1589271A/zh active Pending
- 2002-12-18 NZ NZ533471A patent/NZ533471A/en unknown
- 2002-12-18 EP EP02797421A patent/EP1458723B1/en not_active Expired - Lifetime
- 2002-12-18 JP JP2003562118A patent/JP2005523257A/ja not_active Withdrawn
- 2002-12-18 AU AU2002361785A patent/AU2002361785B2/en not_active Ceased
- 2002-12-18 YU YU53604A patent/YU53604A/sh unknown
- 2002-12-18 MX MXPA04005876A patent/MXPA04005876A/es active IP Right Grant
- 2002-12-18 AT AT02797421T patent/ATE411319T1/de not_active IP Right Cessation
- 2002-12-18 ES ES02797421T patent/ES2314127T3/es not_active Expired - Lifetime
- 2002-12-18 PL PL02370904A patent/PL370904A1/pl not_active Application Discontinuation
- 2002-12-18 DK DK02797421T patent/DK1458723T3/da active
- 2002-12-18 PT PT02797421T patent/PT1458723E/pt unknown
- 2002-12-18 RU RU2004122403/04A patent/RU2330038C2/ru not_active IP Right Cessation
- 2002-12-18 DE DE60229435T patent/DE60229435D1/de not_active Expired - Fee Related
- 2002-12-18 IL IL16254702A patent/IL162547A0/xx unknown
- 2002-12-18 WO PCT/US2002/040598 patent/WO2003062241A1/en active Application Filing
- 2002-12-18 UA UA20040705945A patent/UA78265C2/uk unknown
- 2002-12-18 CA CA002471342A patent/CA2471342A1/en not_active Abandoned
- 2002-12-18 GE GE5693A patent/GEP20063817B/en unknown
- 2002-12-19 UY UY27595A patent/UY27595A1/es not_active Application Discontinuation
- 2002-12-19 AR ARP020105038A patent/AR037950A1/es unknown
-
2004
- 2004-06-16 CO CO04056353A patent/CO5640082A2/es not_active Application Discontinuation
- 2004-06-17 ZA ZA200404812A patent/ZA200404812B/en unknown
- 2004-06-17 HR HR20040567A patent/HRP20040567A2/hr not_active Application Discontinuation
- 2004-06-18 IS IS7324A patent/IS7324A/is unknown
- 2004-07-16 NO NO20043068A patent/NO20043068L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200404812B (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. | |
| ZA200302963B (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. | |
| Ghorab et al. | Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety | |
| US6667313B1 (en) | 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators | |
| ES2310622T3 (es) | Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas. | |
| JP2004523558A (ja) | 縮合環式スクシンイミド化合物およびその類似体、核内ホルモン受容体機能のモジュレーター | |
| JP2004509072A (ja) | 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法 | |
| BRPI0409117A (pt) | compostos n-heterocìclios condensados e seu uso como antagonistas do receptor de crf | |
| CN102149687B (zh) | 作为雄激素受体调节剂的咪唑烷化合物 | |
| KR20090109527A (ko) | Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제 | |
| WO2009033281A1 (en) | Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer | |
| WO2013142390A1 (en) | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors | |
| US7235563B2 (en) | Spirocyclic compounds useful as modulators of nuclear hormone receptor function | |
| WO2021139756A1 (zh) | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 | |
| RU2621708C2 (ru) | Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение | |
| EP4397660A1 (en) | Compound as tyk2/jak1 pseudokinase domain inhibitor, and synthesis and use methods | |
| ZA200210313B (en) | Fused cyclic compounds as modulators of nuclear hormone receptor function. | |
| MXPA03009159A (es) | Ciclohexilfenilos agonistas de vasopresina. | |
| RU2298554C2 (ru) | Конденсированные гетероциклические сукцинимидные соединения | |
| WO2023166450A1 (ko) | 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물 | |
| WO2024208305A1 (zh) | 稠合四环类化合物、其制备方法及其在医药上的应用 | |
| AU2607300A (en) | Pyrrolobenzodiazepine carboxyamide vasopressin agonists | |
| AU2002250163A1 (en) | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
| AU2013208847A1 (en) | Novel heteroarylamide derivatives having antiandrogenic properties |